We report in vivo selection of a severe acute respiratory syndrome coronavirus 2 spike mutation (Q493R) conferring simultaneous resistance to bamlanivimab and etesivimab. This mutation was isolated from a patient who had coronavirus disease and was treated with these drugs.

Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19

Novazzi, Federica
Secondo
;
Genoni, Angelo;Dentali, Francesco;Gasperina, Daniela Dalla;Baj, Andreina
Penultimo
;
Maggi, Fabrizio
Ultimo
2021-01-01

Abstract

We report in vivo selection of a severe acute respiratory syndrome coronavirus 2 spike mutation (Q493R) conferring simultaneous resistance to bamlanivimab and etesivimab. This mutation was isolated from a patient who had coronavirus disease and was treated with these drugs.
COVID-19; Italy; SARS-CoV-2; bamlaniv/etesevimab; coronavirus disease; coronaviruses; receptor-binding motif; respiratory infections; severe acute respiratory syndrome coronavirus 2; spike protein; spike protein escape mutation Q493R; treatment; variant; viruses; zoonoses
Focosi, Daniele; Novazzi, Federica; Genoni, Angelo; Dentali, Francesco; Gasperina, Daniela Dalla; Baj, Andreina; Maggi, Fabrizio
File in questo prodotto:
File Dimensione Formato  
EID-Protein Escape Mutation Q493R after Treatment for COVID-19 - Volume 27, Number 10—October 2021 - Emerging Infectious Diseases journal - CDC.pdf

accesso aperto

Tipologia: Documento in Post-print
Licenza: Creative commons
Dimensione 327.15 kB
Formato Adobe PDF
327.15 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/2114544
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 31
social impact